You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 21817 results
  1. Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs.

    SBC: GEL4MED, INC.            Topic: 200

    Project Summary/AbstractDFUs will affect more than 30% of diabetic patients within their lifetime and costs the US healthcare system over $20 billion annually. Many DFUs fail to heal effectively and require extensive medical intervention. Nearly 50% of DFUs worsen to “tunnel” into deep tissues involving tendons and bones (DTU-DFUs). When this happens, DFUs are susceptible to severe complicatio ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    In this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A conversational agent to support remote care for individuals with substance use disorder

    SBC: DIMAGI, INC.            Topic: NIDA

    PROJECT SUMMARY Substance use disorder (SUD) is a significant public health challenge, and it has been estimated that its effects on healthcare, work productivity, and criminal justice costs the US over $600 billion annually. Engagement with the clinical care team is critical to an individual’s path to SUD recovery; however, limited capacity of and access to addiction treatment providers and tra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults

    SBC: MOAI TECHNOLOGIES, LLC            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Pharmaceutical development of longer-lasting brimonidine eye drops

    SBC: Novus Vision LLC            Topic: NEI

    PROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Medical Device Identifier to Improve Emergency Triage

    SBC: BRIDGESOURCE MEDICAL, CORP.            Topic: R

    Project Summary Abstract Cardiovascular Implantable Electronic Devices (CIEDs) like a Permanent Pacemaker or Implantable Defibrillator are implanted in over 3 million Americans, with the average age of implantation in the 60s, 40% ≥ 70 years old, and 28% ≥ 80 years old. When a patient presents to the Emergency Department (ED) with an unknown CIED, reprogramming of the device is often necessary ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A single dose anti-scarring therapeutic for the cornea

    SBC: DUB BIOLOGICS, INC            Topic: NEI

    Abstract DUB Biologics is developing a therapeutic for the prevention and treatment of corneal scarring through knockdown of a novel target that has been shown to be central to the fibrotic response leading to corneal opacification. Corneal opacification severely impairs the vision of 4.2 million people around the world, 5.1% of the total blind population. Monocular scarring is far more common, af ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement

    SBC: PICCOLO MEDICAL, INC.            Topic: NIA

    Abstract In the United States alone, more than three million peripherally inserted central catheters (PICCs) are placed each year to provide IV therapies, where in about half of cases navigation through the venous system is typically performed blind, or without navigation guidance. Improper PICC placement is relatively common, is costly, and has serious complications for critically-ill patients. U ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Clustered home assessment of visual fields in patients with glaucoma

    SBC: Vivid Vision, Inc.            Topic: NEI

    Project summary/abstractGlaucoma is the second leading cause of irreversible vision loss in Americans. Effective treatment requires the patient to take visual field tests over time, to monitor for progression of visual field loss. In many patients there is no progression, but when it occurs it must be detected as quickly as possible in order to save vision by using a more aggressive treatment. Pat ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government